General reaction for the conversion of testosterone to estradiol catalyzed by aromatase. Steroids are composed of four fused rings (labeled A-D). Aromatase converts the ring labeled "A" into an aromatic state.
The gene expresses two transcript variants. In humans, the gene CYP19, located on chromosome 15q21.1, encodes aromatase. The gene has nine coding exons and a number of alternative non-coding first exons that regulate tissue specific expression.
Aromatase is generally highly present during the differentiation of ovaries. It is also susceptible to environmental influences, particularly temperature. In species with temperature-dependent sex determination, aromatase is expressed in higher quantities at temperatures that yield female offspring. Despite the fact that data suggest temperature controls aromatase quantities, other studies have shown that aromatase can overpower the effects of temperature: if exposed to more aromatase at a male-producing temperature, the organism will develop female and conversely, if exposed to less aromatase at female-producing temperatures, the organism will develop male (see sex reversal). In organisms that develop through genetic sex determination, temperature does not affect aromatase expression and function, suggesting that aromatase is the target molecule for temperature during TSD (for challenges to this argument, see temperature-dependent sex determination). It varies from species to species whether it is the aromatase protein that has different activity at different temperatures or whether the amount of transcription undergone by the aromatase gene is what is temperature-sensitive, but in either case, differential development is observed at different temperatures.
Role in neuroprotection
Aromatase in the brain is usually only expressed in neurons. However, following penetrative brain injury of both mice and zebra finches, it has been shown to be expressed in astrocytes. It has also been shown to decrease apoptosis following brain injury in zebra finches. This is thought to be due to the neuroprotective actions of estrogens, including estradiol. Research has found that two pro-inflammatory cytokines, interleukin-1β (IL-1β) and interleukin-6 (IL-6), are responsible for the induction of aromatase expression in astrocytes following penetrative brain injury in the zebra finch.
A number of investigators have reported on a rather rare syndrome of excess aromatase activity. In boys, it creates gynecomastia, and in girls, precocious puberty and gigantomastia. In both sexes, early epiphyseal closure leads to short stature. This condition is due to mutations in the CYP19A1 gene which encodes aromatase. It is inherited in an autosomal dominant fashion. It has been suggested that the pharaoh Akhenaten and other members of his family may have suffered from this disorder, but more recent genetic tests suggest otherwise. It is one of the causes of familial precocious puberty—a condition first described in 1937.
This syndrome is due to a mutation of gene CYP19 and inherited in an autosomal recessive way. Accumulations of androgens during pregnancy may lead to virilization of a female at birth (males are not affected). Females will have primary amenorrhea. Individuals of both sexes will be tall, as lack of estrogen does not bring the epiphyseal lines to closure.
Inhibition of aromatase
The inhibition of aromatase can cause hypoestrogenism (low estrogen levels). The following natural products have been found to have inhibiting effects on aromatase.
^Vaz AD (2003). "Chapter 1: Cytochrome activation by cytochromes P450: a role for multiple oxidants in the oxidation of substrates". In Fisher M, Lee JK, Obach RE (eds.). Drug metabolizing enzymes: cytochrome P450 and other enzymes in drug discovery and development. Lausanne, Switzerland: FontisMedia SA. ISBN978-0-8247-4293-5.
^Toda K, Shizuta Y (April 1993). "Molecular cloning of a cDNA showing alternative splicing of the 5'-untranslated sequence of mRNA for human aromatase P-450". European Journal of Biochemistry. 213 (1): 383–9. doi:10.1111/j.1432-1033.1993.tb17772.x. PMID8477708.
^Czajka-Oraniec I, Simpson ER (2010). "Aromatase research and its clinical significance". Endokrynologia Polska. 61 (1): 126–34. PMID20205115.
^Gasnier C, Dumont C, Benachour N, Clair E, Chagnon MC, Séralini GE (August 2009). "Glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines". Toxicology. 262 (3): 184–91. doi:10.1016/j.tox.2009.06.006. PMID19539684.
^ abcdDuffy TA, Picha ME, Won ET, Borski RJ, McElroy AE, Conover DO (August 2010). "Ontogenesis of gonadal aromatase gene expression in atlantic silverside (Menidia menidia) populations with genetic and temperature-dependent sex determination". Journal of Experimental Zoology Part A. 313 (7): 421–31. doi:10.1002/jez.612. PMID20623799.
^Garcia-Segura LM, Wozniak A, Azcoitia I, Rodriguez JR, Hutchison RE, Hutchison JB (March 1999). "Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair". Neuroscience. 89 (2): 567–78. doi:10.1016/s0306-4522(98)00340-6. PMID10077336.
^Saldanha CJ, Rohmann KN, Coomaralingam L, Wynne RD (August 2005). "Estrogen provision by reactive glia decreases apoptosis in the zebra finch (Taeniopygia guttata)". Journal of Neurobiology. 64 (2): 192–201. doi:10.1002/neu.20147. PMID15818556.
^Fukami M, Shozu M, Soneda S, Kato F, Inagaki A, Takagi H, Hanaki K, Kanzaki S, Ohyama K, Sano T, Nishigaki T, Yokoya S, Binder G, Horikawa R, Ogata T (June 2011). "Aromatase excess syndrome: identification of cryptic duplications and deletions leading to gain of function of CYP19A1 and assessment of phenotypic determinants". The Journal of Clinical Endocrinology and Metabolism. 96 (6): E1035–43. doi:10.1210/jc.2011-0145. PMID21470988.
^Ziora K, Oświecimska J, Geisler G, Broll-Waśka K, Szalecki M, Dyduch A (2006). "[Familial precocious puberty -- a variant of norm or pathology?]". Endokrynologia, Diabetologia I Choroby Przemiany Materii Wieku Rozwojowego (in Polish). 12 (1): 53–8. PMID16704862.
^Satoh K, Sakamoto Y, Ogata A, Nagai F, Mikuriya H, Numazawa M, Yamada K, Aoki N (July 2002). "Inhibition of aromatase activity by green tea extract catechins and their endocrinological effects of oral administration in rats". Food and Chemical Toxicology. 40 (7): 925–33. doi:10.1016/S0278-6915(02)00066-2. PMID12065214.
^Kapiszewska M, Miskiewicz M, Ellison PT, Thune I, Jasienska G (May 2006). "High tea consumption diminishes salivary 17beta-estradiol concentration in Polish women". The British Journal of Nutrition. 95 (5): 989–95. doi:10.1079/BJN20061755. PMID16611391.
^Le Bail JC, Pouget C, Fagnere C, Basly JP, Chulia AJ, Habrioux G (January 2001). "Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities". Life Sciences. 68 (7): 751–61. doi:10.1016/S0024-3205(00)00974-7. PMID11205867.
^Ye L, Chan FL, Chen S, Leung LK (October 2012). "The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice". The Journal of Nutritional Biochemistry. 23 (10): 1230–7. doi:10.1016/j.jnutbio.2011.07.003. PMID22209285.
^Wang Y, Lee KW, Chan FL, Chen S, Leung LK (July 2006). "The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells". Toxicological Sciences. 92 (1): 71–7. doi:10.1093/toxsci/kfj190. PMID16611627.
^Siler U, Barella L, Spitzer V, Schnorr J, Lein M, Goralczyk R, Wertz K (June 2004). "Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model". FASEB Journal. 18 (9): 1019–21. doi:10.1096/fj.03-1116fje. PMID15084515.
^Om AS, Chung KW (April 1996). "Dietary zinc deficiency alters 5 alpha-reduction and aromatization of testosterone and androgen and estrogen receptors in rat liver". The Journal of Nutrition. 126 (4): 842–8. doi:10.1093/jn/126.4.842. PMID8613886.
^Chen S, Oh SR, Phung S, Hur G, Ye JJ, Kwok SL, Shrode GE, Belury M, Adams LS, Williams D (December 2006). "Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus)". Cancer Research. 66 (24): 12026–34. doi:10.1158/0008-5472.CAN-06-2206. PMID17178902.
Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Zhou J, Sebastian S (December 2001). "Role of aromatase in endometrial disease". The Journal of Steroid Biochemistry and Molecular Biology. 79 (1–5): 19–25. doi:10.1016/S0960-0760(01)00134-0. PMID11850203.
Balthazart J, Baillien M, Ball GF (December 2001). "Phosphorylation processes mediate rapid changes of brain aromatase activity". The Journal of Steroid Biochemistry and Molecular Biology. 79 (1–5): 261–77. doi:10.1016/S0960-0760(01)00143-1. PMID11850233.
Richards JA, Petrel TA, Brueggemeier RW (February 2002). "Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells". The Journal of Steroid Biochemistry and Molecular Biology. 80 (2): 203–12. doi:10.1016/S0960-0760(01)00187-X. PMID11897504.
Balthazart J, Baillien M, Ball GF (May 2002). "Interactions between aromatase (estrogen synthase) and dopamine in the control of male sexual behavior in quail". Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology. 132 (1): 37–55. doi:10.1016/S1096-4959(01)00531-0. PMID11997208.
Meinhardt U, Mullis PE (2002). "The aromatase cytochrome P-450 and its clinical impact". Hormone Research. 57 (5–6): 145–52. doi:10.1159/000058374. PMID12053085.
Carreau S, Bourguiba S, Lambard S, Galeraud-Denis I, Genissel C, Levallet J (July 2002). "Reproductive system: aromatase and estrogens". Molecular and Cellular Endocrinology. 193 (1–2): 137–43. doi:10.1016/S0303-7207(02)00107-7. PMID12161013.
Meinhardt U, Mullis PE (August 2002). "The essential role of the aromatase/p450arom". Seminars in Reproductive Medicine. 20 (3): 277–84. doi:10.1055/s-2002-35374. PMID12428207.
Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S (February 2004). "Organization of the human aromatase p450 (CYP19) gene". Seminars in Reproductive Medicine. 22 (1): 5–9. doi:10.1055/s-2004-823022. PMID15083376.
Simpson ER (February 2004). "Aromatase: biologic relevance of tissue-specific expression". Seminars in Reproductive Medicine. 22 (1): 11–23. doi:10.1055/s-2004-823023. PMID15083377.
Bulun SE, Fang Z, Imir G, Gurates B, Tamura M, Yilmaz B, Langoi D, Amin S, Yang S, Deb S (February 2004). "Aromatase and endometriosis". Seminars in Reproductive Medicine. 22 (1): 45–50. doi:10.1055/s-2004-823026. PMID15083380.
Chen S, Ye J, Kijima I, Kinoshita Y, Zhou D (May 2005). "Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue". The Journal of Steroid Biochemistry and Molecular Biology. 95 (1–5): 17–23. doi:10.1016/j.jsbmb.2005.04.002. PMID15955695.
Lambard S, Silandre D, Delalande C, Denis-Galeraud I, Bourguiba S, Carreau S (May 2005). "Aromatase in testis: expression and role in male reproduction". The Journal of Steroid Biochemistry and Molecular Biology. 95 (1–5): 63–9. doi:10.1016/j.jsbmb.2005.04.020. PMID16019206.
Bulun SE, Imir G, Utsunomiya H, Thung S, Gurates B, Tamura M, Lin Z (May 2005). "Aromatase in endometriosis and uterine leiomyomata". The Journal of Steroid Biochemistry and Molecular Biology. 95 (1–5): 57–62. doi:10.1016/j.jsbmb.2005.04.012. PMID16024248.
Ellem SJ, Risbridger GP (March 2006). "Aromatase and prostate cancer". Minerva Endocrinologica. 31 (1): 1–12. PMID16498360.
Brueggemeier RW, Díaz-Cruz ES (March 2006). "Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches". Minerva Endocrinologica. 31 (1): 13–26. PMID16498361.
Jongen VH, Hollema H, Van Der Zee AG, Heineman MJ (March 2006). "Aromatase in the context of breast and endometrial cancer. A review". Minerva Endocrinologica. 31 (1): 47–60. PMID16498363.
Hiltunen M, Iivonen S, Soininen H (March 2006). "Aromatase enzyme and Alzheimer's disease". Minerva Endocrinologica. 31 (1): 61–73. PMID16498364.